Orphazyme A/S announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme A/S to take on the role as CEO of LEO Pharma A/S. Effective April 1, 2022, Chief Financial Officer (CFO), Anders Vadsholt, will be appointed CEO of Orphazyme.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
859.9 DKK | -3.38% |
|
-3.39% | -35.35% |
27/03 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04/03 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
1st Jan change | Capi. | |
---|---|---|
-35.35% | 4.45M | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.59% | 27.52B | |
-18.07% | 20.87B | |
-14.11% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- ORPHA Stock
- News Orphazyme A/S
- Orphazyme A/S Announces CEO Changes